Newtron Pharms

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and peripheral nervous system. The company's lead product, Xadago (safinamide), is a multi-mechanism drug approved globally for the treatment of Parkinson's disease as an add-on therapy to levodopa. Newron is currently advancing its lead pipeline candidate, evenamide, a first-in-class voltage-gated sodium channel blocker, through late-stage clinical trials for schizophrenia and treatment-resistant schizophrenia. The company leverages its expertise in ion channel modulation to address significant unmet needs in neuropsychiatry and neurology. Headquartered in Milan, Italy, Newron is publicly traded on the SIX Swiss Exchange and maintains a lean operational model focused on high-value R&D.